Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Shanghai ZJ Bio-Tech Co's current 3-Year Share Buyback Ratio was 0.40%.
The historical rank and industry rank for Shanghai ZJ Bio-Tech Co's 3-Year Share Buyback Ratio or its related term are showing as below:
SHSE:688317'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -10.1 Med: 0 Max: 0.4
Current: 0.4
During the past 13 years, Shanghai ZJ Bio-Tech Co's highest 3-Year Share Buyback Ratio was 0.40%. The lowest was -10.10%. And the median was 0.00%.
SHSE:688317's 3-Year Share Buyback Ratio is ranked better than 86.62% of 613
companies
in the Medical Devices & Instruments industry
Industry Median: -2.6
vs SHSE:688317: 0.40
Shanghai ZJ Bio-Tech Co (SHSE:688317) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Shanghai ZJ Bio-Tech Co 3-Year Share Buyback Ratio Related Terms
SHSE:688317 vs ABT, SYK, MDT: 3-Year Share Buyback Ratio Comparison
For the Medical Devices subindustry, Shanghai ZJ Bio-Tech Co's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai ZJ Bio-Tech Co 3-Year Share Buyback Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shanghai ZJ Bio-Tech Co's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Shanghai ZJ Bio-Tech Co's 3-Year Share Buyback Ratio falls into.
Shanghai ZJ Bio-Tech Co 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of 0.40 mean?
Shanghai ZJ Bio-Tech Co (SHSE:688317) has a 3-Year Share Buyback Ratio of 0.40 as of Mar. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Shanghai ZJ Bio-Tech Co and its competitors. According to the industry distribution chart, Shanghai ZJ Bio-Tech Co ranks #82 out of 613 companies in the Medical Devices & Instruments industry, placing it in the top 13.4%.
Is Shanghai ZJ Bio-Tech Co's 3-Year Share Buyback Ratio too high?
Shanghai ZJ Bio-Tech Co's current 3-Year Share Buyback Ratio is 0.40. Based on the distribution chart, Shanghai ZJ Bio-Tech Co ranks #82 out of 613 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai ZJ Bio-Tech Co has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai ZJ Bio-Tech Co's 3-Year Share Buyback Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shanghai ZJ Bio-Tech Co ranks #82 out of 613 companies for 3-Year Share Buyback Ratio. This places Shanghai ZJ Bio-Tech Co in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Medical Devices & Instruments company?
A good 3-Year Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Shanghai ZJ Bio-Tech Co and its competitors. Shanghai ZJ Bio-Tech Co's current 3-Year Share Buyback Ratio is 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai ZJ Bio-Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co (SHSE:688317) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥9.76, compared to a current price of ¥16.13 — trading 65.3% above its estimated fair value. The current 3-Year Share Buyback Ratio is 0.40. Shanghai ZJ Bio-Tech Co's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Shanghai ZJ Bio-Tech Co (SHSE:688317), the current 3-Year Share Buyback Ratio is 0.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai ZJ Bio-Tech Co (SHSE:688317) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co stock appears to be overvalued.
The current stock price of ¥16.13 is trading 65.3% above its estimated GF Value™ of ¥9.76.
GuruFocus considers Shanghai ZJ Bio-Tech Co to be Significantly Overvalued.
Key valuation signals for SHSE:688317:
3-Year Share Buyback Ratio: 0.40
GF Value™: ¥9.76 vs. price of ¥16.13 (65.3% above fair value)
No single metric tells the full story. See the SHSE:688317 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai ZJ Bio-Tech Co Ltd is engaged in research and development, production and sales of genetic diagnostic reagents and instruments and equipment. The rapid real-time fluorescent PCR diagnostic test reagents developed by the company are mainly used in clinical medicine, public health emergencies, entry-exit inspection and quarantine, food inspection, animal husbandry, aquaculture and other fields.
62GF Score
Get the complete analysis for SHSE:688317
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688317 has been successfully added to your 
